Cargando…
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS‐ADONIS trials
BACKGROUND: The use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is complex because impaired renal clearance can cause increased drug levels, and risk of intolerance or adverse events. Due to the propensity for CKD to occur alongside atrial fibrillation/atrial flutter...
Autores principales: | Thind, Munveer, Zareba, Wojciech, Atar, Dan, Crijns, Harry J. G. M., Zhu, Jun, Pak, Hui‐Nam, Reiffel, James, Ludwigs, Ulf, Wieloch, Mattias, Stewart, John, Kowey, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799050/ https://www.ncbi.nlm.nih.gov/pubmed/35019175 http://dx.doi.org/10.1002/clc.23765 |
Ejemplares similares
-
Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials
por: Thind, Munveer, et al.
Publicado: (2020) -
Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies
por: Thind, Munveer, et al.
Publicado: (2022) -
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial
por: Vamos, Mate, et al.
Publicado: (2021) -
Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial
por: Blomström-Lundqvist, Carina, et al.
Publicado: (2023) -
The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk
por: Thind, Munveer, et al.
Publicado: (2020)